Table 3 Top 10 research priorities for retina and uveitis topics.
RETINA 595 Respondents | % of those responding to this survey who judged this research question to be important | Average ranking of this research question by respondents On a scale of 1–10 (1 most important, 10 least) |
Q1 How can the prevention, diagnosis and treatment of dry age-related macular degeneration be improved? | 59.83% (356 respondents) | 2.44 |
Q2 How can the prevention, diagnosis and treatment of wet age related macular degeneration be improved? | 55.80% (332 respondents) | 2.49 |
Q3 How can sight loss due to inherited retinal diseases be prevented or restored? | 56.64% (337 respondents) | 2.54 |
Q4 Visual rehabilitation in eyes with central visual loss due to retinal diseases? | 49.41% (294 respondents) | 3.20 |
Q5 How can the prevention, diagnosis and treatment of diabetic eye disease be improved? | 34.45% (205 respondents) | 3.25 |
Q6 Artificial Intelligence in retinal diseases | 34.62% (206 respondents) | 3.61 |
Q7 How can the prevention, diagnosis and treatment of macular holes be improved? | 36.47% (217 respondents) | 3.63 |
Q8 How can the prevention, diagnosis and treatment of fibrosis as a complication of retinal diseases be improved? | 20.67% (123 respondents) | 4.06 |
Q9 How can the prevention, diagnosis and treatment of ocular inflammatory disease be improved? | 21.51% (128 respondents) | 4.21 |
Q10 How can the prevention, diagnosis and treatment of ocular melanoma be improved? - Cancer can occur in the eye first or affect the eye from other parts of the body. | 15.80% (94 respondents) | 5.12 |
UVEITIS 151 Respondents | Â | Â |
Q1 What are the most effective treatments for ocular and orbital inflammatory diseases? | 53.64% (81 respondents) | 2.62 |
Q2 What causes relapse in ocular inflammatory disease and how long should we treat patients? | 59.60% (90 respondents) | 2.64 |
Q3 What are the best ways to personalise treatment in uveitis and scleritis? | 53.64% (81 respondents) | 2.88 |
Q4 What causes uveitis or scleritis in isolated ocular disease and in systemic disease with associated disease? | 55.63% (84 respondents) | 2.99 |
Q5 Which licensed treatments for systemic inflammatory diseases (but not for uveitis) are effective in inflammatory eye disease? | 42.38% (64 respondents) | 3.12 |
Q6 What are the most effective biomarkers (imaging / non-imaging) to predict relapse or monitor for disease progression in ocular or orbital inflammatory disease? | 48.34% (73 respondents) | 3.21 |
Q7 How can we improve ways to diagnose infectious uveitis? | 33.77% (51 respondents) | 3.55 |
Q8 What are the most effective scoring systems and clinical outcome measures (imaging / non-imaging) of disease and treatment response in ocular or orbital inflammatory disease? | 33.11% (50 respondents) | 3.70 |
Q9 What is the cause and most effective medical management for Thyroid Eye Disease? | 18.54% (28 respondents) | 4.52 |
